ALTERRA Post-Approval Study

NCT ID: NCT05378386

Last Updated: 2025-11-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-05-12

Study Completion Date

2035-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will monitor device performance and outcomes in subjects undergoing implantation of the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent in the post-approval setting

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a single arm, prospective, multicenter post-approval study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Valve Insufficiency Complex Congenital Heart Defect Tetralogy of Fallot Pulmonary Regurgitation RVOT Anomaly

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TPVR

Transcatheter Pulmonary Valve Replacement

Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve System

Intervention Type DEVICE

The Edwards Alterra Adaptive Prestent is designed to reduce the diameter of large irregular right ventricular outflow tracts (RVOTs) and provide a circular, semi-rigid landing zone to place an Edwards SAPIEN 3 transcatheter heart valve (THV).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve System

The Edwards Alterra Adaptive Prestent is designed to reduce the diameter of large irregular right ventricular outflow tracts (RVOTs) and provide a circular, semi-rigid landing zone to place an Edwards SAPIEN 3 transcatheter heart valve (THV).

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Native or surgically-repaired RVOT with severe PR
2. Clinically indicated for pulmonary valve replacement
3. Planned for treatment with the Alterra prestent and SAPIEN 3 THV

Exclusion Criteria

1. Inability to tolerate an anticoagulation/antiplatelet regimen
2. Active bacterial endocarditis or other active infections
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Edwards Lifesciences

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Children's of Alabama

Birmingham, Alabama, United States

Site Status

Arkansas Children's Hospital

Little Rock, Arkansas, United States

Site Status

Cedars Sinai Medical Center

Los Angeles, California, United States

Site Status

Rady Children's Hospital

San Diego, California, United States

Site Status

Stanford University

Stanford, California, United States

Site Status

Colorado Children's Hospital

Aurora, Colorado, United States

Site Status

UF Health Shands Hospital

Gainesville, Florida, United States

Site Status

St. Joseph's Children's Hospital

Tampa, Florida, United States

Site Status

Advocate Children's Hospital

Oak Lawn, Illinois, United States

Site Status

Boston Children's Hospital

Boston, Massachusetts, United States

Site Status

Washington University in St. Louis

St Louis, Missouri, United States

Site Status

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Site Status

Columbia University

New York, New York, United States

Site Status

Duke University

Durham, North Carolina, United States

Site Status

Cincinnati Children's Hospital

Cincinnati, Ohio, United States

Site Status

Nationwide Children's Hospital

Columbus, Ohio, United States

Site Status

UPMC Children's Hospital of Pittsburgh

Pittsburgh, Pennsylvania, United States

Site Status

Le Bonheur Children's Hospital

Memphis, Tennessee, United States

Site Status

Medical City Dallas

Dallas, Texas, United States

Site Status

Children's Memorial Hermann Hospital

Houston, Texas, United States

Site Status

Texas Children's Hospital

Houston, Texas, United States

Site Status

Primary Children's Hospital

Salt Lake City, Utah, United States

Site Status

Seattle Children's Hospital

Seattle, Washington, United States

Site Status

Schneider Children's Medical Center of Israel

Petah Tikva, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Israel

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-11

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

AltaValve Pivotal Trial
NCT06465745 RECRUITING NA
Autus Valve Pivotal Study
NCT05006404 RECRUITING NA
Pulmonic SAPIEN XT THV
NCT02302131 COMPLETED
ALLEVIATE-HF-HD Study
NCT05501652 COMPLETED PHASE1
The ENCIRCLE Trial
NCT04153292 RECRUITING NA